Search

Your search keyword '"Bénédicte Richaud Thiriez"' showing total 12 results
Start Over Author "Bénédicte Richaud Thiriez"
12 results on '"Bénédicte Richaud Thiriez"'

1. Clinical and microbiological characteristics of cystic fibrosis adults never colonized by Pseudomonas aeruginosa: Analysis of the French CF registry.

Author

Réchana Vongthilath, Bénédicte Richaud Thiriez, Clémence Dehillotte, Lydie Lemonnier, Alicia Guillien, Bruno Degano, Marie-Laure Dalphin, Jean-Charles Dalphin, and Patrick Plésiat

Subjects
Medicine, Science
Abstract

Pseudomonas aeruginosa is the main cause of chronic airway infection in cystic fibrosis (CF). However, for unclear reasons some patients are never colonized by P. aeruginosa. The objectives of this study were to better define the clinical, genetic, and microbiological characteristics of such a subpopulation and to identify predictive factors of non-colonization with P. aeruginosa. The French CF patient registry 2013-2014 was used to identify CF patients aged ≥ 20 years. The clinical outcomes, CF Transmembrane conductance Regulator (CFTR) genotypes, and microbiological data of patients reported positive at least once for P. aeruginosa ("Pyo" group, n = 1,827) were compared to those of patients with no history of P. aeruginosa isolation ("Never" group, n = 303). Predictive factors of non-colonization by P. aeruginosa were identified by multivariate logistic regression model with backward selection. Absence of aspergillosis (odds ratio (OR) [95% CI] = 1.64 [1.01-2.66]), absence of diabetes (2.25 [1.21-4.18]), pancreatic sufficiency (1.81 [1.30-2.52]), forced expiratory volume 1 (FEV1) ≥ 80% (3.03 [2.28-4.03]), older age at CF diagnosis (1.03 [1.02-1.04]), and absence of F508del/F508del genotype (2.17 [1.48-3.19]) were predictive clinical factors associated with absence of infection ("Never" group). Microbiologically, this same group was associated with more frequent detection of Haemophilus influenzae and lower rates of Stenotrophomonas maltophilia, Achromobacter xylosoxidans and Aspergillus spp. (all p

Published
2019
Full Text
View/download PDF

2. Rapid Improvement after Starting Elexacaftor–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease

Author

Pierre-Régis Burgel, Isabelle Durieu, Raphaël Chiron, Sophie Ramel, Isabelle Danner-Boucher, Anne Prevotat, Dominique Grenet, Christophe Marguet, Martine Reynaud-Gaubert, Julie Macey, Laurent Mely, Annlyse Fanton, Sébastien Quetant, Lydie Lemonnier, Jean-Louis Paillasseur, Jennifer Da Silva, Clémence Martin, Claire Andrejak, Arnaud Becourt, Julie Mounard, Claire Poulet, Cinthia Rames, Marie Talleux, Marie-Chantal Chevalier, Estelle Darviot, Marie Jouvenot, Caroline Marien, Audrey Paris, Cécile Pelatan, Christine Person, Pascaline Priou, Françoise Troussier, Thierry Urban, Marie-Laure Dalphin, Jean-Charles Dalphin, Alice Ladaurade, Didier Pernet, Bénédicte Richaud-Thiriez, Pauline Roux-Claude, Nathalia Blanc, Vincent Boisserie-Lacroix, Stephanie Bui, Cyrielle Collet, Stéphane Debelleix, Emmanuel Bergot, Jacques Brouard, Karine Campbell, Muriel Laurans, Virginie Ribault, Corinne Borderon, Marie-Christine Heraud, Guillaume Labbe, Sylvie Montcouquiol, Isabelle Petit, Marc Ruivard, Céline Delestrain, Benoit Douvry, Ralph Epaud, Bernard Maitre, Natascha Remus, Guillaume Beltramo, Anne Houzel, Frédéric Huet, Stéphanie Perez, Amale Boldron-Ghaddar, Manuela Scalbert, Rabah Bouzioukh, Charles Simon, Boubou Camara, Rébecca Hamidfar, Catherine Llerena, Isabelle Pin, Antoine Deschildre, Alice Gicquello, Olivier Le Rouzic, Clara Leroy, Nicolas Paris, Thierry Perez, Caroline Thumerelle, Dominique Turck, Nathalie Wizla, Magali Dupuy-Grasset, Jane Languepin, Alexandra Masson-Rouchaud, Céline Menetrey, Stéphane Durupt, Sophie L’Excellent, Raphaele Nove-Josserand, Camille Ohlmann, Phillipe Reix, Quitterie Reynaud, Marie-Christine Werck-Gallois, Mélissandre Baravalle, Bérangère Coltey, Nadine Desmazes-Dufeu, Jean-Christophe Dubus, Clarisse Gautier, Jean-Baptiste Rey, Nathalie Stremler, Davide Caimmi, Margot Devrait, Johan Moreau, Yves Billon, Aurore Blondé, Anne Guillaumot, Sébastien Kiefer, Laura Peretti, Aurélie Tatopoulos, Angélica Tiotiu, Myriam Benhamida, Tiphaine Bihouee, Emmanuel Eschapasse, Adrien Tissot, Marie Giannantonio, Sylvie Leroy, Carole Piccini-Bailly, Johana Pradelli, Jonathan Messika, Véronique Boussaud, Nicolas Carlier, Isabelle Honoré, Dominique Hubert, Reem Kanaan, Céline Bailly-Botuha, Frédérique Chedevergne, Jacques De Blic, Christophe Delacourt, David Drummond, Brigitte Fauroux, Chantal Karila, Muriel Le Bourgeois, Isabelle Sermet, Bertrand Delaisi, Michèle Gerardin, Veronique Houdouin, Laurence Leclainche, Guillaume Aubertin, Laura Berdah, Annick Clement, Harriet Corvol, Nadia Nathan, Blandine Prevost, Nicolas Richard, Aline Tamalet, Jessica Taytard, Guillaume Thouvenin, Barbara Tourniaire, Michel Abely, Katia Bessaci-Kabouya, Sandra Dury, Bruno Ravoninjatovo, Alain Dabadie, Michel Dagorne, Eric Deneuville, Marie Jamin, Mélanie Ribault, Clémentine Vigier, Chantal Belleguic, Graziella Brinchault, Benoit Desrues, Audrey Barzic, Anne Dirou-Prigent, Jean Le Bihan, Krista Revert, Thomas Ropars, Laure Couderc, Stéphane Dominique, Hélène Morisse-Pradier, Stéphanie Pramil, Luc Thiberville, Nathalie Allou, Laurent Enaud, Elsa Gachelin, Eric Huchot, Annabelle Payet, Caroline Perisson, Saguiraly Piyaraly, Sophie Valois, Audrey Herzog, Romain Kessler, Michele Porzio, Laurence Weiss, Laurence Beaumont, Olivier Brugiere, Sylvie Colin, de Verdiere, Elise Cuquemelle, Sandra De Miranda, Adbdul Monem Hamid, François Parquin, Clément Picard, Antoine Roux, Charlotte Roy, François Bremont, Alain Didier, Marion Dupuis, Guillaume Faviez, Géraldine Labouret, Marie Mittaine, Marlène Murris-Espin, Léa Roditis, Laure Cosson, Patrice Diot, Thomas Flament, Charlotte Giraut, Julie Mankikian, Baptiste Arnouat, Gaétane Mousset, Véronique Storni, Philippe Vigneron, Emmanuelle Coirier-Duet, Asma Gabsi, Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hospices Civils de Lyon (HCL), Université de Lyon, Hôpital Arnaud de Villeneuve [CHRU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Fondation ILDYS (ILDYS), Institut du Thorax [Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Hôpital Albert Calmette, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital Foch [Suresnes], CHU Rouen, Normandie Université (NU), INSERM-TRANSFERT [Paris] (IT), Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Rouen Normandie (UNIROUEN), Hôpital Nord [CHU - APHM], Aix Marseille Université (AMU), CHU Bordeaux [Bordeaux], Hôpital Renée Sabran [CHU - HCL], CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Hospitalier Universitaire [Grenoble] (CHU), Vaincre la Mucoviscidose, Association de lutte contre la Mucoviscidose, EFFI-STAT, URC/CIC Paris Descartes Necker Cochin, Hôpital Necker, Institut Desbrest de santé publique (IDESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Supported by Vaincre la Mucoviscidose, Fondation Sauver la Vie, Universite Paris Descartes, Filiere Maladies Rares Muco-CFTR, and Legs PascalBonnet., Participating Investigators of the FrenchCystic Fibrosis Reference Network StudyGroup:Claire Andrejak, Arnaud Becourt, JulieMounard, Claire Poulet, Cinthia Rames, MarieTalleux (Amiens), Marie-Chantal Chevalier,Estelle Darviot, Marie Jouvenot, Caroline Marien,Audrey Paris, C ecile Pelatan, Christine Person,Pascaline Priou, Franc ̧oise Troussier, ThierryUrban (Angers-Le Mans), Marie-Laure Dalphin,Jean-Charles Dalphin, Alice Ladaurade, DidierPernet, B en edicte Richaud-Thiriez, PaulineRoux-Claude (Besanc ̧on), Nathalia Blanc,Vincent Boisserie-Lacroix, Stephanie Bui,Cyrielle Collet, St ephane Debelleix, Julie Macey(Bordeaux), Emmanuel Bergot, JacquesBrouard, Karine Campbell, Muriel Laurans,Virginie Ribault (Caen), Corinne Borderon,Marie-Christine Heraud, Guillaume Labbe,SylvieMontcouquiol, Isabelle Petit, Marc Ruivard(Clermont-Ferrand), C eline Delestrain, BenoitDouvry, Ralph Epaud, Bernard Maitre, NataschaRemus (Cr eteil), Guillaume Beltramo, AnnlyseFanton, Anne Houzel, Fr ed eric Huet, St ephaniePerez (Dijon), AmaleBoldron-Ghaddar, ManuelaScalbert (Dunkerque), Rabah Bouzioukh,Laurent Mely, Charles Simon (Giens), BoubouCamara, R ebecca Hamidfar, Catherine Llerena,Isabelle Pin, S ebastien Quetant (Grenoble), Antoine Deschildre, Alice Gicquello, Olivier LeRouzic, Clara Leroy, Nicolas Paris, Thierry Perez,Anne Prevotat, Caroline Thumerelle, DominiqueTurck, Nathalie Wizla (Lille), Magali Dupuy-Grasset, Jane Languepin, Alexandra Masson-Rouchaud, C eline Menetrey (Limoges), IsabelleDurieu, St ephane Durupt, Sophie L’Excellent,Raphaele Nove-Josserand, Camille Ohlmann,Phillipe Reix, Quitterie Reynaud, Marie-ChristineWerck-Gallois (Lyon), M elissandre Baravalle,B erang ere Coltey, Nadine Desmazes-Dufeu,Jean-Christophe Dubus, Clarisse Gautier, Jean-Baptiste Rey, Martine Reynaud-Gaubert,Nathalie Stremler (Marseille), Davide Caimmi,Rapha€el Chiron, Margot Devrait, Johan Moreau(Montpellier), Yves Billon, Aurore Blond e, AnneGuillaumot, S ebastien Kiefer, Laura Peretti,Aur elie Tatopoulos, Ang elica Tiotiu (Nancy), Myriam Benhamida, Tiphaine Bihouee, IsabelleDanner-Boucher, Emmanuel Eschapasse,Adrien Tissot (Nantes), Marie Giannantonio,Sylvie Leroy, Carole Piccini-Bailly, JohanaPradelli (Nice), Jonathan Messika (Paris, Bichat), V eronique Boussaud, Pierre-R egis Burgel,Nicolas Carlier, Isabelle Honor e, DominiqueHubert, Reem Kanaan, Cl emence Martin (Paris,Cochin), C eline Bailly-Botuha, Fr ed eriqueChedevergne, Jacques De Blic, ChristopheDelacourt, David Drummond, Brigitte Fauroux,Chantal Karila, Muriel Le Bourgeois, IsabelleSermet (Paris, Necker), Bertrand Delaisi,Mich ele Gerardin, Veronique Houdouin,Laurence Leclainche (Paris, Robert Debr e), Guillaume Aubertin, Laura Berdah, AnnickClement, Harriet Corvol, Nadia Nathan, BlandinePrevost, Nicolas Richard, Aline Tamalet, JessicaTaytard, Guillaume Thouvenin, BarbaraTourniaire (Paris, Trousseau), Michel Abely,Katia Bessaci-Kabouya, Sandra Dury, BrunoRavoninjatovo (Reims), Alain Dabadie, MichelDagorne, Eric Deneuville, Marie Jamin, M elanieRibault, Cl ementine Vigier (Rennes – SaintBrieuc), Chantal Belleguic, Graziella Brinchault,Benoit Desrues (Rennes), Audrey Barzic, AnneDirou-Prigent, Jean Le Bihan, Sophie Ramel,Krista Revert, Thomas Ropars (Roscoff), LaureCouderc, St ephane Dominique, ChristopheMarguet, H el ene Morisse-Pradier, St ephaniePramil, Luc Thiberville (Rouen), Nathalie Allou,Laurent Enaud, Elsa Gachelin, Eric Huchot,Annabelle Payet, Caroline Perisson, SaguiralyPiyaraly, Sophie Valois (La R eunion), AudreyHerzog, Romain Kessler, Michele Porzio,Laurence Weiss (Strasbourg), LaurenceBeaumont, Olivier Brugiere, Sylvie Colin deVerdiere, Elise Cuquemelle, Sandra De Miranda,Dominique Grenet, Adbdul Monem Hamid,Franc ̧ois Parquin, Cl ementPicard, Antoine Roux,Charlotte Roy (Suresnes), Franc ̧ois Bremont,Alain Didier, Marion Dupuis, Guillaume Faviez,G eraldine Labouret, Marie Mittaine, Marl eneMurris-Espin, L ea Roditis (Toulouse), LaureCosson, Patrice Diot, Thomas Flament, CharlotteGiraut, JulieMankikian(Tours), Baptiste Arnouat,Ga etane Mousset, V eronique Storni, PhilippeVigneron (Vannes-Lorient), and Emmanuelle Coirier-Duet, and Asma Gabsi (Versailles)

Subjects
Lung Diseases, Male, elexacaftor, Indoles, Cystic Fibrosis, Pyridines, medicine.medical_treatment, Regulator, Aminophenols, Critical Care and Intensive Care Medicine, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, Cystic fibrosis, Gastroenterology, Membrane Potentials, Ivacaftor, 0302 clinical medicine, Prospective Studies, 030212 general & internal medicine, Chloride Channel Agonists, Aged, 80 and over, Middle Aged, Transmembrane protein, Drug Combinations, Quinolines, Female, France, medicine.drug, Adult, Pulmonary and Respiratory Medicine, congenital, hereditary, and neonatal diseases and abnormalities, medicine.medical_specialty, cystic fibrosis transmembrane conductance regulator modulators, Adolescent, Pulmonary disease, Young Adult, 03 medical and health sciences, Internal medicine, lung transplantation, medicine, Humans, Lung transplantation, In patient, Aged, [SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics, business.industry, Editorials, medicine.disease, 030228 respiratory system, Tezacaftor, Pyrazoles, business
Abstract

International audience; Rationale: Elexacaftor-tezacaftor-ivacaftor is a CFTR (cystic fibrosis [CF] transmembrane conductance regulator) modulator combination, developed for patients with CF with at least one Phe508del mutation. Objectives: To evaluate the effects of elexacaftor-tezacaftor- ivacaftor in patients with CF and advanced respiratory disease. Methods: A prospective observational study, including all patients aged ⩾12 years and with a percent-predicted FEV1 (ppFEV1)

Published
2021
Full Text
View/download PDF

3. Exophiala dermatitidis Revealing Cystic Fibrosis in Adult Patients with Chronic Pulmonary Disease

Author

Bénédicte Richaud-Thiriez, Marie Gainet-Brun, Jean-Philippe Bouchara, B. Cimon, Heloise Pana-Katatali, Marie-Claire Malinge, Frédéric Grenouillet, Yohann Le Govic, Christine Person, Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Groupe d'Étude des Interactions Hôte-Pathogène (GEIHP), Université d'Angers (UA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Département de Biochimie et Génétique [Angers], Université d'Angers (UA)-Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Astellas, Pfizer, and MSD

Subjects
0301 basic medicine, food.ingredient, Veterinary (miscellaneous), 030106 microbiology, Applied Microbiology and Biotechnology, Microbiology, Cystic fibrosis, 03 medical and health sciences, Elderly, food, Exophiala, Humans, Medicine, [SDV.MP.MYC]Life Sciences [q-bio]/Microbiology and Parasitology/Mycology, Aged, Aged, 80 and over, Bronchiectasis, Lung Diseases, Fungal, biology, business.industry, Respiratory disease, biology.organism_classification, medicine.disease, Cystic fibrosis transmembrane conductance regulator, Late diagnosis, 3. Good health, Exophiala dermatitidis, Phaeohyphomycosis, medicine.anatomical_structure, Immunology, biology.protein, Female, business, Agronomy and Crop Science, Dimorphic fungus, Rasamsonia, Respiratory tract
Abstract

International audience; Cystic fibrosis (CF) is a genetic inherited disease due to mutations in the gene cystic fibrosis transmembrane conductance regulator (CFTR). Because of the huge diversity of CFTR mutations, the CF phenotypes are highly heterogeneous, varying from typical to mild form of CF, also called atypical CF. These atypical features are more frequently diagnosed at adolescence or adulthood, and among clinical signs and symptoms leading to suspect a mild form of CF, colonization or infection of the respiratory tract due to well-known CF pathogens should be a warning signal. Exophiala dermatitidis is a melanized dimorphic fungus commonly detected in respiratory specimens from CF patients, but only very rarely from respiratory specimens from non-CF patients. We described here two cases of chronic colonization of the airways by E. dermatitidis, with recurrent pneumonia and hemoptysis in one patient, which led clinicians to diagnose mild forms of CF in these elderly patients who were 68- and 87-year-old. These cases of late CF diagnosis suggest that airway colonization or respiratory infections due to E. dermatitidis in patients with bronchiectasis should led to search for a mild form of CF, regardless of the age and associated symptoms. On a broader level, in patients with chronic respiratory disease and recurrent pulmonary infections, an allergic bronchopulmonary mycosis or an airway colonization by CF-related fungi like E. dermatitidis or some Aspergillus, Scedosporium or Rasamsonia species, should be considered as potential markers of atypical CF and should led clinicians to conduct investigations for CF diagnosis.

Published
2017
Full Text
View/download PDF

4. Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis

Author

Pierre-Régis Burgel, Anne Munck, Isabelle Durieu, Raphaël Chiron, Laurent Mely, Anne Prevotat, Marlene Murris-Espin, Michele Porzio, Michel Abely, Philippe Reix, Christophe Marguet, Julie Macey, Isabelle Sermet-Gaudelus, Harriet Corvol, Stéphanie Bui, Lydie Lemonnier, Clémence Dehillotte, Jennifer Da Silva, Jean-Louis Paillasseur, Dominique Hubert, Julie Mounard, Claire Poulet, Cinthia Rames, Christine Person, Françoise Troussier, Thierry Urban, Marie-Laure Dalphin, Jean-Claude Dalphin, Didier Pernet, Bénédicte Richaud-Thiriez, Mickael Fayon, Julie Macey-Caro, Karine Campbell, Muriel Laurans, Corinne Borderon, Marie-Christine Heraud, André Labbé, Sylvie Montcouquiol, Laurence Bassinet, Natascha Remus, Annlyse Fanton, Anne Houzel-Charavel, Frédéric Huet, Stéphanie Perez-Martin, Amale Boldron-Ghaddar, Manuela Scalbert, Boubou Camara, Catherine Llerena, Isabelle Pin, Sébastien Quétant, Aurélie Cottereau, Antoine Deschildre, Alice Gicquello, Thierry Perez, Lidwine Stervinou-Wemeau, Caroline Thumerelle, Benoit Wallaert, Nathalie Wizla, Jane Languepin, Céline Ménétrey, Magalie Dupuy-Grasset, Lucie Bazus, Clelia Buchs, Virginie Jubin, Marie-Christine Werck-Gallois, Catherine Mainguy, Thomas Perrin, Agnès Toutain-Rigolet, Stéphane Durupt, Quitterie Reynaud, Raphaele Nove-Josserand, Melisande Baravalle-Einaudi, Bérangère Coltey, Nadine Dufeu, Jean-Christophe Dubus, Nathalie Stremler, Davide Caimmi, Yves Billon, Jocelyne Derelle, Sébastien Kieffer, Anne-Sophie Pichon, Cyril Schweitzer, Aurélie Tatopoulos, Sarah Abbes, Tiphaine Bihouée, Isabelle Danner-Boucher, Valérie David, Alain Haloun, Adrien Tissot, Sylvie Leroy, Carole Bailly-Piccini, Annick Clément, Aline Tamalet, Isabelle Honoré, Reem Kanaan, Clémence Martin, Cécile Bailly, Frédérique Chédevergne, Jacques De Blic, Brigitte Fauroux, Murielle Le Bourgeois, Bertrand Delaisi, Michèle Gérardin, Michel Abély, Bruno Ravoninjatovo, Chantal Belleguic, Benoit Desrues, Graziella Brinchault, Michel Dagorne, Eric Deneuville, Sylvaine Lefeuvre, Anne Dirou, Jean Le Bihan, Sophie Ramel, Stéphane Dominique, Annabelle Payet, Romain Kessler, Vincent Rosner, Laurence Weiss, Sandra de Miranda, Dominique Grenet, Abdoul Hamid, Clément Picard, François Brémont, Alain Didier, Géraldine Labouret, Marie Mittaine, Marlène Murris-Espin, Laurent Têtu, Laure Cosson, Charlotte Giraut, Anne-Cécile Henriet, Julie Mankikian, Sophie Marchand, Sandrine Hugé, Véronique Storni, Emmanuelle Coirier-Duet, CHU Cochin [AP-HP], Service de Médecine Interne - Centre Hospitalier Lyon Sud, Hospices Civils de Lyon (HCL)-Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre de Ressources et de Compétences en Mucoviscidose [Lyon] (CRCM [Lyon]), Hospices Civils de Lyon (HCL)-CHU Lyon-Hôpital Renée Sabran [CHU - HCL], Hôpital Albert Calmette, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Toulouse [Toulouse], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Service de pédiatrie médicale et médecine de l'adolescent [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Centre de recherche Croissance et signalisation (UMR_S 845), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de pneumologie [CHU Trousseau], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Trousseau [APHP], Centre de Ressources et de Compétences de la Mucoviscidose (CRCM), Hôpital des Enfants, CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Association Vaincre La Mucoviscidose, Institut Cochin (IC UM3 (UMR 8104 / U1016)), EFFI-STAT, CIC Cochin Pasteur (CIC 1417), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP]-Hôtel-Dieu-Université Paris Descartes - Paris 5 (UPD5)-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Mucoviscidose: physiopathologie et phénogénomique [CRSA], Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université - Faculté de Médecine (SU FM), Sorbonne Université (SU), Centre de Ressources et de Compétences en Mucoviscidose [CHU Toulouse] (CRCM Toulouse), Service Pneumologie et allergologie pédiatrique [CHU Toulouse], Pôle Enfants [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle Enfants [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu-Université Paris Descartes - Paris 5 (UPD5)-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe hospitalier Broca-Université Paris Descartes - Paris 5 (UPD5)-Hôtel-Dieu-Hôpital Cochin [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

Subjects
Male, Cystic Fibrosis, Gastrointestinal Diseases, [SDV]Life Sciences [q-bio], Aminopyridines, Quinolones, Critical Care and Intensive Care Medicine, Logistic regression, Aminophenols, Cystic fibrosis, Body Mass Index, Ivacaftor, chemistry.chemical_compound, 0302 clinical medicine, Deprescriptions, Forced Expiratory Volume, Medicine, 030212 general & internal medicine, Fatigue, 2. Zero hunger, biology, Lumacaftor, Headache, lumacaftor–ivacaftor, Cystic fibrosis transmembrane conductance regulator, 3. Good health, Anti-Bacterial Agents, Drug Combinations, Treatment Outcome, Administration, Intravenous, Female, France, medicine.drug, Pulmonary and Respiratory Medicine, Adult, medicine.medical_specialty, Metrorrhagia, Adolescent, Nutritional Status, 03 medical and health sciences, Young Adult, Internal medicine, Product Surveillance, Postmarketing, Humans, Benzodioxoles, Adverse effect, Bronchial Spasm, business.industry, Editorials, Myalgia, medicine.disease, Discontinuation, Dyspnea, Logistic Models, 030228 respiratory system, chemistry, Cough, Multivariate Analysis, biology.protein, postmarketing study, business, Body mass index
Abstract

International audience; Rationale: Lumacaftor-ivacaftor is a CFTR (cystic fibrosis transmembrane conductance regulator) modulator combination recently approved for patients with cystic fibrosis (CF) homozygous for the Phe508del mutation.Objectives: To evaluate the safety and effectiveness of lumacaftor-ivacaftor in adolescents (≥12 yr) and adults (≥18 yr) in a real-life postapproval setting.Methods: The study was conducted in the 47 CF reference centers in France. All patients who initiated lumacaftor-ivacaftor from January 1 to December 31, 2016, were eligible. Patients were evaluated for lumacaftor-ivacaftor safety and effectiveness over the first year of treatment following the French CF Learning Society's recommendations.Measurements and Main Results: Among the 845 patients (292 adolescents and 553 adults) who initiated lumacaftor-ivacaftor, 18.2% (154 patients) discontinued treatment, often owing to respiratory (48.1%, 74 patients) or nonrespiratory (27.9%, 43 patients) adverse events. In multivariable logistic regression, factors associated with increased rates of discontinuation included adult age group, percent predicted FEV1 (ppFEV1) less than 40%, and numbers of intravenous antibiotic courses during the year before lumacaftor-ivacaftor initiation. Patients with continuous exposure to lumacaftor-ivacaftor showed an absolute increase in ppFEV1 (+3.67%), an increase in body mass index (+0.73 kg/m2), and a decrease in intravenous antibiotic courses by 35%. Patients who discontinued treatment had significant decrease in ppFEV1, without improvement in body mass index or decrease in intravenous antibiotic courses.Conclusions: Lumacaftor-ivacaftor was associated with improvement in lung disease and nutritional status in patients who tolerated treatment. Adults who discontinued lumacaftor-ivacaftor, often owing to adverse events, were found at high risk of clinical deterioration.

Published
2019
Full Text
View/download PDF

5. Clinical and microbiological characteristics of cystic fibrosis adults never colonized by Pseudomonas aeruginosa: Analysis of the French CF registry

Author

Bénédicte Richaud Thiriez, Lydie Lemonnier, Clémence Dehillotte, Patrick Plésiat, Alicia Guillien, Jean-Charles Dalphin, Rechana Vongthilath, Marie-Laure Dalphin, Bruno Degano, Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre National de la Recherche Scientifique (CNRS), Service de bactériologie [Besançon], and Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)

Subjects
Male, Cystic Fibrosis, Pulmonology, Cystic Fibrosis Transmembrane Conductance Regulator, Pathology and Laboratory Medicine, Aspergillosis, medicine.disease_cause, Cystic fibrosis, Gastroenterology, Haemophilus influenzae, Endocrinology, 0302 clinical medicine, Stenotrophomonas Maltophilia, Forced Expiratory Volume, Medicine and Health Sciences, Registries, 030212 general & internal medicine, Lung, ComputingMilieux_MISCELLANEOUS, Disease Resistance, Haemophilus Influenzae, Multidisciplinary, biology, Age Factors, Fungal Diseases, Pseudomonas Aeruginosa, Achromobacter xylosoxidans, Middle Aged, Bacterial Pathogens, 3. Good health, Stenotrophomonas maltophilia, Infectious Diseases, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, Medical Microbiology, Genetic Diseases, Medicine, Female, France, Pathogens, medicine.symptom, Research Article, Adult, medicine.medical_specialty, Clinical Pathology, Endocrine Disorders, Science, Haemophilus, Microbiology, Young Adult, 03 medical and health sciences, Autosomal Recessive Diseases, Pseudomonas, Internal medicine, Diabetes Mellitus, medicine, Humans, Pseudomonas Infections, Microbial Pathogens, Retrospective Studies, Clinical Genetics, Bacteria, Pseudomonas aeruginosa, business.industry, Sputum, Organisms, Biology and Life Sciences, Odds ratio, medicine.disease, biology.organism_classification, Fibrosis, Clinical Microbiology, 030228 respiratory system, Metabolic Disorders, Respiratory Infections, business, Follow-Up Studies, Developmental Biology
Abstract

Pseudomonas aeruginosa is the main cause of chronic airway infection in cystic fibrosis (CF). However, for unclear reasons some patients are never colonized by P. aeruginosa. The objectives of this study were to better define the clinical, genetic, and microbiological characteristics of such a subpopulation and to identify predictive factors of non-colonization with P. aeruginosa. The French CF patient registry 2013–2014 was used to identify CF patients aged ≥ 20 years. The clinical outcomes, CF Transmembrane conductance Regulator (CFTR) genotypes, and microbiological data of patients reported positive at least once for P. aeruginosa (“Pyo” group, n = 1,827) were compared to those of patients with no history of P. aeruginosa isolation (“Never” group, n = 303). Predictive factors of non-colonization by P. aeruginosa were identified by multivariate logistic regression model with backward selection. Absence of aspergillosis (odds ratio (OR) [95% CI] = 1.64 [1.01–2.66]), absence of diabetes (2.25 [1.21–4.18]), pancreatic sufficiency (1.81 [1.30–2.52]), forced expiratory volume 1 (FEV1) ≥ 80% (3.03 [2.28–4.03]), older age at CF diagnosis (1.03 [1.02–1.04]), and absence of F508del/F508del genotype (2.17 [1.48–3.19]) were predictive clinical factors associated with absence of infection (“Never” group). Microbiologically, this same group was associated with more frequent detection of Haemophilus influenzae and lower rates of Stenotrophomonas maltophilia, Achromobacter xylosoxidans and Aspergillus spp. (all p

Published
2019
Full Text
View/download PDF

6. Replies to 'Is the home environment an important factor in the occurrence of fungal events in cystic fibrosis?'

Author

Steffi Rocchi, Jean-Charles Dalphin, Bénédicte Richaud-Thiriez, Frédéric Grenouillet, Laurence Millon, Gabriel Reboux, Coralie Barrera, Laboratoire Chrono-environnement ( LCE ), Université Bourgogne Franche-Comté ( UBFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC ), Université de Franche-Comté ( UFC ), Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)

Subjects
Male, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Cystic Fibrosis, 030501 epidemiology, Cystic fibrosis, Aspergillus fumigatus, [ SDV.EE.SANT ] Life Sciences [q-bio]/Ecology, environment/Health, 03 medical and health sciences, 0302 clinical medicine, medicine, Humans, Intensive care medicine, ComputingMilieux_MISCELLANEOUS, [SDV.EE.SANT]Life Sciences [q-bio]/Ecology, environment/Health, Inhalation exposure, Inhalation Exposure, biology, Home environment, business.industry, Aspergillosis, Allergic Bronchopulmonary, biology.organism_classification, medicine.disease, 030228 respiratory system, Air Pollution, Indoor, Pediatrics, Perinatology and Child Health, Female, 0305 other medical science, business
Abstract

International audience

Published
2016

7. Evaluation of mold exposure in cystic fibrosis patients' dwellings and allergic bronchopulmonary risk

Author

Jean-Charles Dalphin, Frédéric Grenouillet, Laurence Millon, Bénédicte Richaud-Thiriez, Gabriel Reboux, Coralie Barrera, Steffi Rocchi, Laboratoire Chrono-environnement ( LCE ), Université Bourgogne Franche-Comté ( UBFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC ), Hôpital Jean Minjoz, Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), and Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)

Subjects
[SDV.EE.SANT]Life Sciences [q-bio]/Ecology, environment/Health, Pulmonary and Respiratory Medicine, Inhalation exposure, biology, business.industry, Fungal contamination, Environmental exposure, medicine.disease, biology.organism_classification, Cystic fibrosis, 3. Good health, Aspergillus fumigatus, Microbiology, [ SDV.EE.SANT ] Life Sciences [q-bio]/Ecology, environment/Health, Fungal sensitization, Pediatrics, Perinatology and Child Health, Immunology, medicine, Fungal colonization, Pediatrics, Perinatology, and Child Health, Allergic bronchopulmonary aspergillosis, business, ComputingMilieux_MISCELLANEOUS
Abstract

Very few studies have been conducted on cystic fibrosis (CF) patients' exposure to the indoor environment and, to our knowledge, there are no studies dealing with the link between specific fungal environmental exposure at home and fungal colonization resulting in allergic bronchopulmonary aspergillosis (ABPA). Fungal exposure of CF adult patients with ABPA (n=4) with fungal sensitization (n=7) and with no ABPA (n=5) was assessed in 16 homes by dust sampling with electrostatic dust fall collectors (EDCs). Aspergillus fumigatus was specifically quantified by real-time quantitative polymerase chain reactions (qPCRs), and A. fumigatus DNA concentrations were significantly higher in homes of ABPA patients (p

Published
2015

8. New Commercially Available IgG Kits and Time-Resolved Fluorometric IgE Assay for Diagnosis of Allergic Bronchopulmonary Aspergillosis in Patients with Cystic Fibrosis

Author

Gabriel Reboux, Coralie Barrera, Jean-Charles Dalphin, Frédéric Grenouillet, Audrey Laboissière, Bénédicte Rognon, Laurence Millon, Steffi Rocchi, Bénédicte Richaud-Thiriez, Sandrine Roussel, Laboratoire Chrono-environnement ( LCE ), Université Bourgogne Franche-Comté ( UBFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC ), Université de Franche-Comté ( UFC ), Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)

Subjects
0301 basic medicine, Microbiology (medical), Adult, Male, Antigens, Fungal, Adolescent, Cystic Fibrosis, 030106 microbiology, Clinical Biochemistry, Immunology, Blotting, Western, Enzyme-Linked Immunosorbent Assay, Immunoglobulin E, Aspergillosis, Immunoglobulin G, Microbiology, Aspergillus fumigatus, [ SDV.EE.SANT ] Life Sciences [q-bio]/Ecology, environment/Health, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Diagnostic Laboratory Immunology, medicine, Immunology and Allergy, Humans, skin and connective tissue diseases, Antibodies, Fungal, [SDV.EE.SANT]Life Sciences [q-bio]/Ecology, environment/Health, Aspergillus, biology, Aspergillosis, Allergic Bronchopulmonary, Glucose-6-Phosphate Isomerase, Allergens, Middle Aged, biology.organism_classification, medicine.disease, Precipitin, 3. Good health, 030228 respiratory system, biology.protein, Female, Reagent Kits, Diagnostic, Antibody, Allergic bronchopulmonary aspergillosis, Sugar Alcohol Dehydrogenases
Abstract

Allergic bronchopulmonary aspergillosis (ABPA) is difficult to diagnose; diagnosis relies on clinical, radiological, pathological, and serological criteria. Our aim was to assess the performance of two new commercially available kits and a new in-house assay: an Aspergillus fumigatus enzyme-linked immunosorbent assay (ELISA) IgG kit (Bordier Affinity Products), an Aspergillus Western blotting IgG kit (LDBio Diagnostics), and a new in-house time-resolved fluorometric IgE assay (dissociation-enhanced lanthanide fluorescent immunoassay, or DELFIA) using recombinant proteins from an Aspergillus sp. recently developed by our laboratory for ABPA diagnosis in a retrospective study that included 26 cystic fibrosis patients. Aspergillus fumigatus -specific IgG levels measured by a commercial ELISA kit were in accordance with the level of precipitins currently used in our lab. The ELISA kit could accelerate and help standardize ABPA diagnosis. Aspergillus fumigatus -specific IgE levels measured by ImmunoCAP (Phadia) with A. fumigatus M3 antigen and by DELFIA with a purified protein extract of A. fumigatus were significantly correlated ( P < 10 −6 ). The results with recombinant antigens glucose-6-phosphate isomerase and mannitol-1-phosphate dehydrogenase were encouraging but must be confirmed with sera from more patients. The DELFIA is an effective tool that can detect specific IgE against more fungal allergens than can be detected with other commercially available tests.

Published
2014

9. Dosage des IgE par immunofluorométrie en temps retardé (DELFIA ® ) appliqué au diagnostic d’aspergillose bronchopulmonaire allergique (ABPA) d’une cohorte de patients atteints de mucoviscidose

Author

Gabriel Reboux, Coralie Barrera, Frédéric Grenouillet, Sandrine Roussel, Bénédicte Richaud-Thiriez, Bénédicte Rognon, Laurence Millon, Jean-Charles Dalphin, Steffi Rocchi, and Audrey Laboissière

Subjects
Infectious Diseases
Abstract

Objet de l’etude Le diagnostic de l’ABPA chez les patients atteints de mucoviscidose est delicat et repose sur un ensemble d’arguments cliniques, serologiques et radiographiques (Stevens, 2003). De nombreuses etudes tentent d’ameliorer le serodiagnostic en identifiant les proteines immunoreactives avec les IgE et/ou les IgG et en les synthetisant en antigenes recombinants (AgR). Mais leurs efficacites sont variables selon les etudes. Notre laboratoire a produit 5 AgR issus d’Aspergillus (Millon, 2012) dans le cadre de recherches sur la maladie du poumon de fermier. Quatre d’entre eux ont egalement ete reveles en Western blot puis identifies par spectrometrie de masse avec des serums de patients ABPA par l’equipe de Singh (2010). L’objectif de l’etude etait de developper la technique DELFIA® pour mesurer le taux d’IgE specifiques, d’Ag somatiques purifies (AgS) d’A. fumigatus et d’AgR afin d’evaluer les performances diagnostiques de ce nouveau test chez les patients atteints de mucoviscidose et d’ABPA. Methodes Pour la validation de la technique DELFIA®, 53 serums de patients anonymes ont ete utilises. Et 26 patients atteints de mucoviscidose ont ete collectes, dont 5 ont une ABPA. Les resultats obtenus ont ete compares aux resultats d’immunoCAP M3 (Thermo Scientific) utilise en routine pour la mesure du taux d’IgE specifiques d’A. fumigatus. Un extrait d’AgS et 5 AgR : NAD-dependant formate deshydrogenase, Glucose-6-phosphate isomerase (G6Pi), Glu/Leu/Phe/Val deshydrogenase, Mannitol-1-phosphate deshydrogenase (Man1P) et Enolase ont ete testes. La technique DELFIA® est realisee en plaque de 96 puits ou sont fixes les Ag puis par incubations successives : le serum, l’anticorps secondaire liee a une biotine puis la streptavidine couplee a l’Europium. La mesure de la fluorescence est obtenue apres une excitation a 340 nm. Resultats Le test realise avec des AgS d’A. fumigatus montre une bonne reproductibilite et une bonne correlation avec le resultat d’immunoCAP M3 (Spearman, p-value Conclusions L’utilisation de la Man1P pour le serodiagnostic de l’ABPA peut apporter l’avantage de la standardisation, cependant l’efficacite du test est amelioree uniquement avec l’utilisation simultanee d’AgS d’A. fumigatus. Le DELFIA® est un outil prometteur pour le dosage d’IgE specifiques et apporte l’avantage de pouvoir utiliser de nombreux Ag non disponibles dans le commerce. Recemment nous l’avons utilise afin de mettre en evidence un eventuel role de l’exposition professionnelle dans la survenue d’allergies d’ouvriers travaillant dans des plate-formes de compostage (n = 179/6 Ag) et de travailleurs agricoles exposes a de la poussiere de ble (n = 291/14Ag).

Published
2015
Full Text
View/download PDF

10. Génotypage d’ Exophiala dermatitidis par polymorphisme des microsatellites et suivi de la colonisation des patients atteints de mucoviscidose

Author

D. Le Bihan, Bénédicte Richaud-Thiriez, Gabriel Reboux, F. Larcher-Grenouillet, Frédéric Grenouillet, and M. Machouart

Subjects
Infectious Diseases
Abstract

De nombreux micromycetes peuvent coloniser et infecter les voies respiratoires des patients atteints de mucoviscidose. Les « levures noires » du genre Exophiala sont retrouvees chez 2 a 20 % de ces patients et des cas d’infections pulmonaires prouvees ont ete decrits. L’espece Exophiala dermatitidis represente plus de 90 % des souches isolees de ces patients. L’objectif de ce travail a ete de developper une technique de genotypage d’E. dermatitidis par analyse du polymorphisme de microsatellites, et de l’appliquer aux souches de patients atteints de mucoviscidose suivis au CHRU de Besancon colonises par E. dermatitidis . Treize marqueurs microsatellites ont ete identifies et testes sur un panel de cinq souches d’ E. dermatitidis sans lien epidemiologique. Les fragments obtenus apres PCR ont ete analyses en analyse de fragments (polymorphisme de la taille des amplicons). Quatre cibles ont ete selectionnees et evaluees sur 25 souches d’ E. dermatitidis sans lien epidemiologique (isolats cliniques et environnementaux), permettant la determination du pouvoir discriminant de la methode par le calcul de l’indice de Hunter D. La specificite des PCR a ete evaluee avec un panel de 11 souches d’especes proches ( Exophiala phaeomuriformis , Exophiala jeanselmei , Rhinocladiella similis ). Le pouvoir discriminant D du panel associant les 4 microsatellites selectionnes a ete de 0,94. Les cibles se sont revelees specifiques d’ E. dermatitidis , sans amplification des autres especes. L’etude sur une cohorte de 13 patients atteints de mucoviscidose avec 71 isolats d’ E. dermatitidis (1 a 21 isolats par patient sur une periode de 70 mois) a montre que chaque patient etait colonise par un seul clone d’ E. dermatitidis . Un meme clone a ete identifie chez 7 patients sur 13. La methode de genotypage d’ E. dermatitidis par polymorphisme des microsatellites s’est revelee discriminante et a permis la caracterisation des souches colonisant les patients atteints de mucoviscidose. L’existence d’un clone dominant commun parmi les souches isolees de patients et les souches environnementales de Franche-Comte appelle a une meilleure connaissance de l’environnement domestique de ces patients, afin d’identifier les sources environnementales a l’origine de leur colonisation pulmonaire par E. dermatitidis .

Published
2016
Full Text
View/download PDF

11. Évaluation de l’exposition aux moisissures des patients atteints de mucoviscidose présentant une aspergillose bronchopulmonaire allergique

Author

Laurence Millon, Bénédicte Richaud-Thiriez, Gabriel Reboux, Frédéric Grenouillet, Coralie Barrera, Steffi Rochi, and Jean-Charles Dalphin

Subjects
Infectious Diseases
Abstract

Objet de l’etude L’objectif de cette etude etait d’evaluer la contamination fongique de logements de patients atteints de mucoviscidose, notamment de mesurer par PCR quantitative la contamination par Aspergillus fumigatus , et de relier ces donnees au risque de survenue d’ABPA chez ces patients. Methodes Des prelevements environnementaux ont ete realises a l’aide de capteur electrostatique de poussiere dans 16 logements de patients atteints de mucoviscidose. Ces capteurs ont analyse par culture, et par qPCR specifique ciblant A. fumigatus comme decrit precedemment (Scherer et al., 2014). Quatre sur 16 patients presentaient une ABPA selon les criteres de Stevens (Stevens et al., 2003), 7/16 presentaient une sensibilisation fongique (presence de precipitines contre les antigenes d’ A. fumigatus ) et 5/16 patients ne presentaient ni ABPA ni sensibilisation fongique. Resultats A. fumigatus a ete detecte en culture dans 5 des 16 logements (4 logements de patients sensibilises et un logement de patient ABPA). Les autres especes isolees etaient A. flavus et A. nidulans . Les quantites d’ADN d’ A. fumigatus les plus elevees (3,4 a 6,5 fg/μL) ont ete mesurees dans les logements des 4 patients presentant une ABPA et de 2 patients avec des antecedents d’ABPA, en remission au moment de l’etude. Tous les autres patients avaient des concentrations d’ADN d’ A. fumigatus dans leur logement inferieures a 2,5 fg/μL. Ainsi les concentrations d’ADN d’ A. fumigatus etaient significativement plus elevees dans les logements de patients avec ABPA ( p Conclusion Nos resultats indiquent que la contamination fongique de l’environnement interieur pourrait etre un facteur favorisant l’ABPA et suggerent l’interet de faire des enquetes environnementales au domicile des patients atteints de mucoviscidose, pour prevenir le risque d’ABPA. Cette etude montre egalement que la technique de qPCR, qui mesure les spores viables et non viables, permet, mieux que la culture, d’evaluer le risque environnemental dans le cadre des maladies allergiques.

Published
2015
Full Text
View/download PDF

12. Brain natriuretic peptide blood levels in the differential diagnosis of dyspnea

Author

Simon Weber, Francois Heloire, Laure Cabanes, Yvonne Fulla, Catherine Vuillemard, Bénédicte Richaud-Thiriez, and Daniel Dusser

Subjects
Pulmonary and Respiratory Medicine, Male, medicine.medical_specialty, Heart disease, medicine.drug_class, Diastole, Critical Care and Intensive Care Medicine, Diagnosis, Differential, Pulmonary Disease, Chronic Obstructive, Predictive Value of Tests, Internal medicine, Natriuretic Peptide, Brain, medicine, Natriuretic peptide, Humans, Aged, Heart Failure, Ejection fraction, business.industry, Diastolic heart failure, Middle Aged, medicine.disease, Brain natriuretic peptide, Obstructive lung disease, Dyspnea, Heart failure, Cardiology, Female, Cardiology and Cardiovascular Medicine, business
Abstract

Study objectives: In dyspneic patients without left ventricular enlargement, it may be difficult to differentiate between obstructive lung disease and diastolic heart failure. Determination of plasma brain natriuretic peptide (BNP) levels, known to increase with ventricular stretch, may be of clinical relevance in this situation. We compared the discriminant power of BNP blood levels and of echocardiography in patients with either chronic obstructive lung disease or diastolic heart failure. Patients: Twenty-six New York Heart Association class III dyspneic patients with normal left ventricular systolic function were enrolled: 17 patients with chronic obstructive lung disease and 9 patients with unequivocal diastolic heart failure. Results: Echocardiographic data were unable to accurately differentiate between the two groups, whereas BNP levels were significantly and markedly higher in patients with diastolic heart failure when compared to those with obstructive lung disease (224 240 pg/mL vs 14 12 pg/mL, p < 0.0001). Conclusions: These preliminary results warrant a prospective, large-scale evaluation of the value of BNP assay for determining diastolic dysfunction, a common cause of dyspnea in elderly patients, and differentiating it from other diagnoses such as obstructive lung disease. (CHEST 2001; 120:2047–2050)

Published
2001

Catalog

Books, media, physical & digital resources
See catalog results